Literature DB >> 24613158

Continuous flow left ventricular assist device technology has influenced wait times and affected donor allocation in cardiac transplantation.

Sharven Taghavi1, Senthil N Jayarajan1, Eugene Komaroff2, Abeel A Mangi3.   

Abstract

OBJECTIVE: Bridge to transplantation patients with continuous flow left ventricular assist devices (cfLVADs) are assigned United Network for Organ Sharing status 1A or 1B priority while awaiting orthotopic heart transplantation. We investigated the influence of cfLVAD on the waitlist times and organ allocation.
METHODS: The United Network for Organ Sharing database was examined from 2005 to 2012 for patients with cfLVAD and pulsatile flow LVAD (pLVAD). These 2 cohorts were compared with patients who did not receive LVAD.
RESULTS: Of 16,476 total orthotopic heart transplantations, 3270 (19.8%) were performed on patients with an LVAD as a bridge to transplantation. The cfLVAD group had the longest total waitlist time (259.6 days) compared with the pLVAD (134.6 days) and non-LVAD (121.7 days) groups (P < .001). The cfLVAD group spent more time in status 1A (44.7 days) than did the pLVAD (32.1 days) and non-LVAD (16.4 days) cohorts (P < .001). The median waitlist survival was better for the cfLVAD group (1234.0 days) than in the pLVAD (441.0 days) and non-LVAD (471.0 days) groups (P < .001). The cfLVAD recipients were older, had a greater body mass index, and more often had diabetes than did pLVAD and non-LVAD patients. The cfLVAD cohort received hearts from older, more often male donors, with a greater body mass index. Post-transplant survival was not significantly different among the 3 groups on Kaplan-Meier analysis (P = .12).
CONCLUSIONS: Despite being older, less favorable recipients, the cfLVAD patients spent more time in status 1A and had greater waitlist survival. This might allow cfLVAD patients to receive preferred donor hearts, which might allow for better post-transplant survival.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24613158     DOI: 10.1016/j.jtcvs.2014.02.001

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  What's new in clinical solid organ transplantation by 2013.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-12-24

Review 2.  Adult heart transplant: indications and outcomes.

Authors:  M Chadi Alraies; Peter Eckman
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

3.  Long-term continuous-flow left ventricular assist devices (LVAD) as bridge to heart transplantation.

Authors:  Matteo Pozzi; Raphaël Giraud; Piergiorgio Tozzi; Karim Bendjelid; Jacques Robin; Philippe Meyer; Jean François Obadia; Carlo Banfi
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

4.  High-speed visualization of disturbed pathlines in axial flow ventricular assist device under pulsatile conditions.

Authors:  Fang Yang; Robert L Kormos; James F Antaki
Journal:  J Thorac Cardiovasc Surg       Date:  2015-06-30       Impact factor: 5.209

5.  Impact of Continuous Flow Left Ventricular Assist Device on Heart Transplant Candidates: A Multi-State Survival Analysis.

Authors:  Massimiliano Carrozzini; Tomaso Bottio; Raphael Caraffa; Jonida Bejko; Olimpia Bifulco; Alvise Guariento; Carlo Mario Lombardi; Marco Metra; Danila Azzolina; Dario Gregori; Marny Fedrigo; Chiara Castellani; Vincenzo Tarzia; Giuseppe Toscano; Antonio Gambino; Vjola Jorgji; Enrico Ferrari; Annalisa Angelini; Gino Gerosa
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

6.  Comparing open gastrostomy tube to percutaneous endoscopic gastrostomy tube in heart transplant patients.

Authors:  Vishnu Ambur; Sharven Taghavi; Senthil Jayarajan; John Gaughan; Yoshiya Toyoda; Elizabeth Dauer; Lars Ola Sjoholm; Abhijit Pathak; Thomas Santora; Amy J Goldberg
Journal:  Ann Med Surg (Lond)       Date:  2016-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.